Drug, Cosmetic & Toiletry Wholesaling in European Union 2026: Industry Statistics & Trends

The Drug, Cosmetic & Toiletry Wholesaling industry in the European Union acts as a critical distribution bridge linking chemical, pharmaceutical, and cosmetic manufacturers with pharmacies, hospitals, and retail outlets across the single market. The sector operates under stringent European regulatory frameworks that ensure public safety, batch traceability, and product efficacy. According to official Eurostat trade data, extra-EU exports of medicinal and pharmaceutical products grew by 16% in 2025 compared to 2024, reaching a record high of €366.19 billion (source: Eurostat 2026), reflecting robust global and internal demand for medical and hygiene commodities. Moving forward, the industry i

Industry snapshot

Key public data points

Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.

What does the Drug, Cosmetic & Toiletry Wholesaling in European Union industry cover?

This industry encompasses the business-to-business distribution and wholesale merchant trade of pharmaceutical goods, medical instruments, perfumes, cosmetics, and personal toiletries within the European Union. Operators manage complex supply chains, specialized climate-controlled storage facilities, and logistical networks designed to safely preserve and transport fragile chemical formulations and sterile medical products. The scope includes both domestic distribution inside member states and intra-community trade across EU borders.

• •Classified under NACE Rev. 2 codes 46.46 (Wholesale of pharmaceutical goods) and 46.45 (Wholesale of perfume and cosmetics).
• •Includes the wholesale distribution of prescription medicines, over-the-counter drugs, medical supplies, skincare, and oral hygiene products.
• •Excludes the direct retail sale to consumers, which falls under retail trade and pharmacy regulations.

Who operates in the industry and how is it structured?

The European wholesale market for drugs and cosmetics features a dual-layered operational structure that pairs massive multinational distribution networks with smaller, localized specialty distributors. Large-scale operators capitalize on bulk purchasing power and optimized transnational logistics, whereas specialized regional wholesalers cater to specific national health service models or localized consumer cosmetic preferences. The distribution infrastructure relies heavily on automated warehousing and adherence to strict good distribution practices.

• •Germany represents the EU's largest manufacturing and distribution hub, commanding 26% of the EU's total sold industrial production value in 2024 (source: Eurostat 2025).
• •The infrastructure handles multi-billion euro trade corridors, with the United States and Switzerland serving as the top external trading partners.
• •Small and medium-sized enterprises (SMEs) represent a large portion of individual operators by company count, focusing on niche organic cosmetic or medical device lines.

What drives demand in the industry?

Demand for wholesaled pharmaceuticals and toiletries within the EU is structurally reinforced by secular demographic shifts and systemic health spending. The continent's rapidly aging population continuously elevates the consumption of chronic disease treatments, medical aids, and specialized anti-aging dermatological products. Concurrently, heightened public focus on preventive personal hygiene and wellness keeps the baseline demand for toiletries resilient against macroeconomic fluctuations.

• •Extra-EU imports of medicinal and pharmaceutical products surged by 21% in 2025 to reach €145.68 billion, highlighting reliance on external supply chains (source: Eurostat 2026).
• •Public and private healthcare expenditures across EU member nations dictate seasonal procurement volumes for pharmaceutical wholesalers.
• •Consumer behavioral shifts toward sustainable, bio-based cosmetics drive retail replenishment orders for specialized product portfolios.

Who are the notable companies in the industry?

The competitive environment is intensely fierce, with dominant pan-European corporations competing alongside national healthcare logistics providers. Competitors differentiate themselves based on supply chain speed, geographical coverage, digital ordering integrations, and compliance track records. Major integrated groups frequently operate both wholesale networks and retail pharmacy chains to achieve vertical efficiency.

• •Phoenix Pharmahandel GmbH & Co KG stands as a prominent European pharmaceutical wholesaler and retailer with an expansive cross-border presence.
• •Celesio AG (part of McKesson Europe) maintains extensive wholesale distribution operations feeding thousands of pharmacies across multiple member states.
• •Alliance Healthcare, operating under Cencora, Inc., functions as one of the largest pharmaceutical wholesalers serving thousands of independent EU pharmacies.
• •L'Oréal S.A. and Beiersdorf AG interact directly with this wholesale layer, utilizing specialized cosmetic distributors to stock selective retail channels.

What are the recent trends and outlook?

The industry's near-term outlook remains highly dynamic, characterized by record-setting financial totals and digital transformation initiatives. Supply chain reshoring and the creation of strategic healthcare stockpiles within the EU have driven record trade balances across the single market. Wholesalers are increasingly investing in tracking technologies and automated fulfillment to mitigate labor shortages and lower processing errors.

• •The EU's trade surplus in medicinal and pharmaceutical products hit a record high of €220.51 billion in 2025 (source: Eurostat 2026).
• •The overall manufacturing value of basic pharmaceutical products inside the EU achieved a historic peak of €54.00 billion in 2024 (source: Eurostat 2025).
• •B2B e-commerce platforms are replacing traditional manual ordering systems, streamlining transactions between wholesalers and pharmacies.

How is the industry regulated?

Compliance within this sector is non-negotiable and governs every facet of daily operations from temperature validation during shipping to exact serial verification. Wholesalers must strictly respect both European-wide directives and local national health mandates to secure and retain their operating licenses. These regulations are designed to completely insulate the legal supply chain from counterfeit medicines or unsafe cosmetic ingredients.

• •Importers and distributors must strictly adhere to EU Good Distribution Practice (GDP) guidelines and obtain formal Wholesale Distribution Authorisations (WDA).
• •The EU Falsified Medicines Directive (Directive 2011/62/EU) mandates end-to-end verification and tamper-evident packaging features on prescription packs.
• •Cosmetic wholesaling is strictly governed by the EU Cosmetics Regulation (Regulation EC No 1223/2009), ensuring ingredient safety and compliance before distribution.

Government, statistical and trade sources used for this Claight analysis.

• Eurostat International Trade in Medicinal and Pharmaceutical Products 2026 ·
• Eurostat Industrial Production Statistics 2025 ·
• European Commission Directorate-General for Trade Access2Markets 2026 ·
• European Parliament and Council Regulation (EC) No 1223/2009